These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 10449565

  • 1. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology.
    Filippi M, Rovaris M, Capra R, Gasperini C, Prandini F, Martinelli V, Horsfield MA, Bastianello S, Sormani MP, Pozzilli C, Comi G.
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):386-9. PubMed ID: 10449565
    [Abstract] [Full Text] [Related]

  • 2. Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients.
    Rovaris M, Capra R, Martinelli V, Gasperini C, Prandini F, Pozzilli C, Comi G, Filippi M.
    J Neurol Sci; 1999 Dec 15; 171(2):130-4. PubMed ID: 10581379
    [Abstract] [Full Text] [Related]

  • 3. Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.
    Rovaris M, Mastronardo G, Prandini F, Bastianello S, Comi G, Filippi M.
    J Neurol Sci; 1999 Apr 01; 164(2):148-52. PubMed ID: 10402026
    [Abstract] [Full Text] [Related]

  • 4. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
    Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C.
    J Neurol Neurosurg Psychiatry; 1996 Sep 01; 61(3):251-8. PubMed ID: 8795595
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis.
    Filippi M, Rovaris M, Gasperini C, Capra R, Bastianello S, Kuhne I, Yousry TA.
    J Neuroimaging; 1998 Apr 01; 8(2):88-93. PubMed ID: 9557146
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C, Pozzilli C, Bastianello S, Giugni E, Horsfield MA, Koudriavtseva T, Galgani S, Paolillo A, Haggiag S, Millefiorini E, Fieschi C.
    J Neurol Neurosurg Psychiatry; 1999 Nov 01; 67(5):579-84. PubMed ID: 10519861
    [Abstract] [Full Text] [Related]

  • 9. Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis.
    Rovaris M, Bastianello S, Capra R, Comi G, Yousry TA, Filippi M.
    Magn Reson Imaging; 1999 Sep 01; 17(7):985-8. PubMed ID: 10463648
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL, Calabresi PA, Kieseier BC, Liu S, You X, Fiore D, Hung S.
    BMC Neurol; 2017 Feb 10; 17(1):29. PubMed ID: 28183276
    [Abstract] [Full Text] [Related]

  • 13. Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.
    Koudriavtseva T, Pozzilli C, Fiorelli M, Gasperini C, Bagnato F, Galgani S, Frontoni M, Ciccarelli O, Bastianello S.
    Mult Scler; 1998 Oct 10; 4(5):403-7. PubMed ID: 9839299
    [Abstract] [Full Text] [Related]

  • 14. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E, Sloan R, Andersson PB, Goodkin D.
    Rev Neurol (Paris); 1999 Oct 10; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [Abstract] [Full Text] [Related]

  • 15. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S.
    BMC Neurol; 2014 Dec 31; 14():240. PubMed ID: 25551571
    [Abstract] [Full Text] [Related]

  • 16. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis.
    Gasperini C, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, Filippi M.
    Magn Reson Imaging; 2000 Jul 07; 18(6):761-3. PubMed ID: 10930786
    [Abstract] [Full Text] [Related]

  • 18. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.
    Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, Prandini F, Horsfield MA, Martinelli V, Bastianello S, Kühne I, Pozzilli C, Comi G.
    Brain; 1998 Oct 07; 121 ( Pt 10)():2011-20. PubMed ID: 9798753
    [Abstract] [Full Text] [Related]

  • 19. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis.
    Filippi M, Capra R, Campi A, Colombo B, Prandini F, Marcianò N, Gasparotti R, Comi G.
    J Neurol Neurosurg Psychiatry; 1996 May 07; 60(5):526-30. PubMed ID: 8778257
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of MRI activity before and during interferon beta-1a therapy.
    Waubant E, Goodkin DE, Sloan R, Andersson PB.
    Neurology; 1999 Sep 11; 53(4):874-6. PubMed ID: 10489060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.